Long-term MHC class II presentation of the EBV lytic protein BHRF1 by EBV latently infected B cells following capture of BHRF1 antigen

Journal of Immunology

Volumn 175, Issue 12, 2005, Pages 7939-7946

  Landais, Elise ^a   Saulquin, Xavier ^a   Bonneville, Marc ^a   Houssaint, Elisabeth ^a  

^a INSTITUT DE BIOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN BHRF1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN BHRF1; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS PROTEIN;

ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL SPECIFICITY; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE DELETION; HUMAN; HUMAN CELL; INFECTION CONTROL; LYMPHOBLASTOID CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN ANALYSIS;

EID: 29144514701     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.12.7939     Document Type: Article

References (49)

1. Kieff E., and A. B. Rickinson. 2001. Epstein-Barr virus and its replication. In Fields Virology, B. N. Fileds, D. M. Knipe, and P. M. Howley, eds. Lippincott-Raven, Philadelphia, pp. 2511-2573.
2. Babcock, G. J., L. L. Decker, M. Volk, and D. A. Thorley-Lawson. 1998. EBV persistence in memory B cells in vivo. Immunity 9: 395-404.
3. Rickinson A. B., and E. Kieff. 2001. Epstein-Barr virus. In Fields Virology. D. M. Knipe, P. M. Howley, R. M. Chanock, J. L. Melnick, T. P. Monath, B. Roizman, and S. E. Strauss, eds. Lippincott Williams & Wilkins, Philadelphia, pp. 2575-2627.
4. Boshoff, C. and R. Weiss. 2002. AIDS-related malignancies. Nat. Rev. Cancer 2: 373-382.
5. Yao, Q. Y., R. J. Tierney, D. Croom-Carter, D. Dukers, G. M. Cooper, C. J. Ellis, M. Rowe, and A. Rickinson. 1996. Frequency of multiple Epstein-Barr virus infections in T-cell-immunocompromised individuals. J. Virol. 70: 4884-4894.
6. Scotet, E., J. David-Ameline, M.-A. Peyrat, A. Moreau-Aubry, D. Pinezon, A. Lim, J. Even, G. Semana, J.-M. Berthelot, R. Breathnach, et al. 1996. T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis. J. Exp. Med. 184: 1791-1800.
7. Steven, N. M., N. Annels, A. Kumar, A. Leese, M. G. Kurilla, and A. B. Rickinson. 1997. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J. Exp. Med. 185: 1605-1617.
8. Tan, L. C., N. Gudgeon, N. E. Annels, P. Hansasuta, C. A. O'Callaghan, S. Rowland-Jones, A. J. McMichael, A. B. Rickinson, and M. F. C. Callan. 1999. A re-evaluation of the frequency of CDS+ T cells specific for EBV in healthy virus carriers. J Immunol. 162: 1827-1835.
9. Scotet, E., M.-A. Peyrat, X. Saulquin, C. Retiere, C. Couedel, F. Davodeau, N. Dulphy, A. Toubert, J. D. Bignon, A. Lim, et al. 1999. Frequent enrichment for CD8 T cells reactive against common herpes viruses in chronic inflammatory lesions: towards a reassessment of the physiopathological significance of T cell clonal expansions found in autoimmune inflammatory processes. Eur. J. Immunol. 29: 973-985.
10. Saulquin, X., C. Ibisch, M.-A. Peyrat, E. Scotet, M. Hourmant, H. Vie, M. Bonneville, and E. Houssaint. 2000. A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening. Ear. J. Immunol 30: 2531-2539.
11. - immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. J. Exp. Med. 201: 349-360.
12. Khanna, R., and S. R. Burrows. 2000. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu. Rev. Microbial. 54: 19-48.
13. Khanna, R., S. R. Burrows, P. M. Steigerwald-Mullen, D. J, Moss, M. G. Kurilla, and L. Cooper. 1997. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) though the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing. Int. Immunol. 9: 1537-1543.
14. + EBV-specific CTLs. J. Immunol. 158: 3619-3625.
15. + T-helper 1 responses. J. Virol. 75: 8649-8659.
16. + T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J. Exp. Med. 191: 1649-1660.
17. + Th1 cells kill Burkitt's lymphoma cells. J. Immunol 169: 1593-1603.
18. + T cells. Cancer Res. 62: 7195-7199.
19. + T cells specific for an MHC class II promiscuous epitope. J. Immunol 169: 2172-2179.
20. + T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. J. Virol. 179: 4896-4907.
21. + T cell response to Epstein-Barr virus during primary and persistent infection. J. Exp. Med. 198: 903-911.
22. + T cell clones. J. Virol. 65: 3821-3828.
23. + virus-specific cytotoxic T cells which recognize Epstein-Barr virus lytic antigen BHRF1. Virology 219: 489-492.
24. + T cells during primary infection. J. Immunol 170: 2590-2598.
25. Landais, E., X. Saulquin, E. Scotet, L. Trautmann, M.-A. Peyrat, J. L. Yates, W. W. Kwok, M. Bonneville, and E. Houssaint, 2004. Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1. Blood 103: 1408-1416.
26. Feederle, R., M. Kost, M., M. Baumann, A. Janz, E. Drouet, W. Hammerscmidt, and H. J, Delecluse. 2000. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two tranactivators. EMBO J. 19: 3080-3089.
27. Lee, M. A., and J. L. Yates. 1992. BHRF1 of Epstein-Barr virus, which is homologous to human proto-oncogene bcl2, is not essential for transformation of B cells or for virus replication in vitro. J. Virol. 66: 1899-1906.
28. Huang, Q., A. M. Petros, H. W. Virgin, S. W. Fesik, and E. T. Olejniczak. 2003. Solution structure of the BHRF1 protein from Epstein-Barr virus, a homologue of human Bcl-2. J. Mol. Biol. 332: 1123-1130.
29. Ellis, S. A., C. Taylor, and A. J. McMichael. 1982. Recognition of HLA-B27 and related antigens by a monoclonal antibody. Hum. Immunol. 5: 49-59.
30. Kumar, J., S. Okada, C. Clayberger, and A. M. Krensky. 2001. Granulysin: a novel antimicrobial. Expert Opin. Invest. Drugs 10: 321-329.
31. 2+ signaling modulates cytolytic T lymphocyte effector functions. J. Exp. Med. 187: 1057-1067.
32. Kataoka, T., N. Shinohara, H. Takayama, K. Takaku, S. Kondo, and K. Nagai. 1996. Concanamycin A, a powerful tool of characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J. Immunol. 156: 3678-3686.
33. Li, J. H., D. Rosen, D. Ronen, C. K. Behrens, P. H. Krammer, W. R. Clark, and C. Berke. 1998. The regulation of CD95 ligand expression and function in CTL. J. Imnumol. 161: 3943-3949.
34. Pinet, V., M. S. Malnati, and E. O. Long. 1994. Two processing pathways for the MHC class II-restricted presentation of endogenous influenza virus antigen. J. Immunol. 152: 4852-4860.
35. Austin, P. J., E. Flemington, C. N. Yandava, J. L. Strominger, and S. H. Speck. 1988. Complex transcription of the Epstein-Barr virus BamHI fragment H rightward open reading frame I (BHRF1) in latently and lytically infected B lymphocytes. PTOC. Natl. Acad. Sci. USA 85: 3678-3682.
36. Oudejans, J. J., A. J. van den Brule, N. M. Jiwa, P. C. de Bruin, G. J. Ossenkoppele, P. van der valk, J. M. Walboomers, and C. J. Meijer. 1995. BHRF1, the Epstein-Barr virus (EBV) homologue of the BCL-2 protooncogene. is transcribed in EBV-associated B-cell lymphomas and in reactive lymphocytes. Blood 86: 1893-1902.
37. Pearson, G. R., J. Luka, L. Petti, J. Sample, M. Birkenbach, D. Braun, and E. Kieff. 1987. identification of an Epstein-Barr virus early gene encoding a second component of the restricted early antigen complex. Virology 160: 151-161.
38. Chou, S. P., C. H. Tsai, L. Ly, L. My, and J. Y. Chen. 2004. Characterization of monoclonal antibody of the Epstein-Barr virus BHRF1 protein, a homologue of Bcl-2. Hybrid Hybridomics 23: 29-37.
39. Murray, P. G., L. J. Swinnen, C. M. Constandinou, J. M. Pyle, T. J. Carr, J. M. Hardwick, and Ambinder, R. F. 1996. BCL-2 but not its Epstein-Barr virus-encoded homologue. BHRF1, is commonly expressed in posttransplantation lymphoproliferative disorders. Blood 87: 706-711.
40. Pfeffer, S., M. Zavolan, F. A. Grasser, M. Chien, J. J. Russo, J. Ju, B. John, A. J. Enright, D. Marks, C. Sander, and T. Tuschl. 2004. Identification of virus-encoded MicroRNAs. Science 304: 734-736.
41. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med 179: 1109-1118.
42. Watts, C. 1997, Capture and processing of exogenous antigens for presentation on MHC molecules. Antut. Rev. Immunol. 15: 821-850.
43. Pathak, S. S., and J. S. Blum. 2000. Endocytic recycling is required for the presentation of an exogenous peptide via MHC class II molecules. Tragic I: 561-569.
44. Rudensk-y, A. Y., P. Preston-Hurlburt, B. K. Al-Ramadi, J. Rothbard, and C. A. Jimeway CA. 1992. Truncation variants of peptides isolated from MHC class II molecules suggest sequence motifs. Nature 359: 429-431.
45. Lanzavecchia, A., P. A. Reid, and C. Watts. 1992. Irreversible association of peptides with class II MHC molecules in living cells. Nature 357: 249-252.
46. Lazarski, C. A., F. A. Chaves, S. A. Jenks, S. Wu, K. A. Richards, J. M, Weaver, and A. J. Sant. 2005, The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. Immunity 23: 29-40.
47. Paludan, C. Schmid, D., Landthaler, M., Vockerodt, M., Kube, D., Tuschl, T., and Munz, C. 2005. Endogenous MHC class II processing of a viral nuclear antigen after authophagy. Science 307: 593-596.
48. Morrison, T. E., A. Mauser, A. Wong, J. P. Ting, and S. C. Kenney. 2001. Inhibition of IFN-γ signaling by an Epstein-Barr virus immediate-earty protein. Immunity 15: 787-799.
49. Hegde, N. R., M. S. Chevalier, and D. C. Johnson. 2003. Viral inhibition of MHC class II antigen presentation. Trends Immunol. 24: 278-285.